Andexanet proves effective as an antidote to factor Xa inhibitors

Early experience with andexanet alfa in patients experiencing a serious bleed on rivaroxaban, apixaban or enoxaparin has shown it effectively inhibits the anti-factor Xa drugs and is associated with clinical haemostasis. Presented at the ESC congress in Rome and published simultaneously in the New England Journal of Medicine the ongoing ANNEXA-4 study enrolled patients who had ...

Already a member?

Login to keep reading.

© 2021 the limbic